Literature DB >> 25164586

Magnetic resonance imaging striatal volumes: a biomarker for clinical trials in Huntington's disease.

Elizabeth H Aylward1.   

Abstract

An abundance of research shows that magnetic resonance imaging (MRI) striatal volumes decrease long before diagnosis of Huntington's disease (HD) and closely track disease progression. Additional research indicates that these volumetric measures meet important criteria for a biomarker that can be used in clinical trials: They are 1) objectively measureable; 2) able to predict known endpoints; and 3) associated with known mechanisms of pathology of the disease. Researchers should consider formal application to regulatory agencies for biomarker status of volumetric MRI striatal measures, because these measures are anticipated to contribute significantly in the assessment of treatment effectiveness in HD.
© 2014 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  Huntington's disease; MRI; biomarker; striatal volume

Mesh：

Substances：

Year:  2014        PMID： 25164586      PMCID： PMC4479278          DOI： 10.1002/mds.26013

Source DB:  PubMed          Journal:  Mov Disord        ISSN： 0885-3185            Impact factor:   10.338


  47 in total

Review 1.  Biomarkers and surrogate endpoints: preferred definitions and conceptual framework.

Authors: 
Journal:  Clin Pharmacol Ther       Date:  2001-03       Impact factor: 6.875

2.  Structural MR image processing using the BRAINS2 toolbox.

Authors:  Vincent A Magnotta; Greg Harris; Nancy C Andreasen; Daniel S O'Leary; William T C Yuh; Dan Heckel
Journal:  Comput Med Imaging Graph       Date:  2002 Jul-Aug       Impact factor: 4.790

3.  Deformation tensor morphometry of semantic dementia with quantitative validation.

Authors:  C Studholme; V Cardenas; R Blumenfeld; N Schuff; H J Rosen; B Miller; M Weiner
Journal:  Neuroimage       Date:  2004-04       Impact factor: 6.556

4.  Potential endpoints for clinical trials in premanifest and early Huntington's disease in the TRACK-HD study: analysis of 24 month observational data.

Authors:  Sarah J Tabrizi; Ralf Reilmann; Raymund A C Roos; Alexandra Durr; Blair Leavitt; Gail Owen; Rebecca Jones; Hans Johnson; David Craufurd; Stephen L Hicks; Christopher Kennard; Bernhard Landwehrmeyer; Julie C Stout; Beth Borowsky; Rachael I Scahill; Chris Frost; Douglas R Langbehn
Journal:  Lancet Neurol       Date:  2011-12-02       Impact factor: 44.182

5.  Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity.

Authors:  H Diana Rosas; David H Salat; Stephanie Y Lee; Alexandra K Zaleta; Vasanth Pappu; Bruce Fischl; Doug Greve; Nathanael Hevelone; Steven M Hersch
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

6.  Assessment of reliability of multi-site neuroimaging via traveling phantom study.

Authors:  Sylvain Gouttard; Martin Styner; Marcel Prastawa; Joseph Piven; Guido Gerig
Journal:  Med Image Comput Comput Assist Interv       Date:  2008

7.  Clinical impairment in premanifest and early Huntington's disease is associated with regionally specific atrophy.

Authors:  Rachael I Scahill; Nicola Z Hobbs; Miranda J Say; Natalie Bechtel; Susie M D Henley; Harpreet Hyare; Douglas R Langbehn; Rebecca Jones; Blair R Leavitt; Raymund A C Roos; Alexandra Durr; Hans Johnson; Stéphane Lehéricy; David Craufurd; Christopher Kennard; Stephen L Hicks; Julie C Stout; Ralf Reilmann; Sarah J Tabrizi
Journal:  Hum Brain Mapp       Date:  2011-11-18       Impact factor: 5.038

8.  Reduced basal ganglia volume associated with the gene for Huntington's disease in asymptomatic at-risk persons.

Authors:  E H Aylward; J Brandt; A M Codori; R S Mangus; P E Barta; G J Harris
Journal:  Neurology       Date:  1994-05       Impact factor: 9.910

9.  Biological and clinical manifestations of Huntington's disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data.

Authors:  Sarah J Tabrizi; Douglas R Langbehn; Blair R Leavitt; Raymund Ac Roos; Alexandra Durr; David Craufurd; Christopher Kennard; Stephen L Hicks; Nick C Fox; Rachael I Scahill; Beth Borowsky; Allan J Tobin; H Diana Rosas; Hans Johnson; Ralf Reilmann; Bernhard Landwehrmeyer; Julie C Stout
Journal:  Lancet Neurol       Date:  2009-07-29       Impact factor: 44.182

10.  Feasibility of multi-site clinical structural neuroimaging studies of aging using legacy data.

Authors:  Christine Fennema-Notestine; Anthony C Gamst; Brian T Quinn; Jenni Pacheco; Terry L Jernigan; Leon Thal; Randy Buckner; Ron Killiany; Deborah Blacker; Anders M Dale; Bruce Fischl; Brad Dickerson; Randy L Gollub
Journal:  Neuroinformatics       Date:  2007-11-13
View more
  8 in total

Review 1.  Statistical modeling of Huntington disease onset.

Authors:  Tanya P Garcia; Karen Marder; Yuanjia Wang
Journal:  Handb Clin Neurol       Date:  2017

2.  Early grey matter changes in structural covariance networks in Huntington's disease.

Authors:  Emma M Coppen; Jeroen van der Grond; Anne Hafkemeijer; Serge A R B Rombouts; Raymund A C Roos
Journal:  Neuroimage Clin       Date:  2016-10-12       Impact factor: 4.881

3.  [11C]SCH23390 binding to the D1-dopamine receptor in the human brain-a comparison of manual and automated methods for image analysis.

Authors:  Per Stenkrona; Granville J Matheson; Simon Cervenka; Pontus Plavén Sigray; Christer Halldin; Lars Farde
Journal:  EJNMMI Res       Date:  2018-08-02       Impact factor: 3.138

4.  Structural neuroimaging differentiates vulnerability from disease manifestation in colombian families with Huntington's disease.

Authors:  Maria Del C Valdés Hernández; Janna Abu-Hussain; Xinyi Qiu; Josef Priller; Mario Parra Rodríguez; Mariana Pino; Sandra Báez; Agustín Ibáñez
Journal:  Brain Behav       Date:  2019-07-05       Impact factor: 2.708

5.  Myelin Breakdown in Human Huntington's Disease: Multi-Modal Evidence from Diffusion MRI and Quantitative Magnetization Transfer.

Authors:  José Bourbon-Teles; Sonya Bells; Derek K Jones; Elizabeth Coulthard; Anne Rosser; Claudia Metzler-Baddeley
Journal:  Neuroscience       Date:  2017-06-01       Impact factor: 3.590

6.  Preventing amyotrophic lateral sclerosis: insights from pre-symptomatic neurodegenerative diseases.

Authors:  Michael Benatar; Joanne Wuu; Caroline McHutchison; Ronald B Postuma; Bradley F Boeve; Ronald Petersen; Christopher A Ross; Howard Rosen; Jalayne J Arias; Stephanie Fradette; Michael P McDermott; Jeremy Shefner; Christine Stanislaw; Sharon Abrahams; Stephanie Cosentino; Peter M Andersen; Richard S Finkel; Volkan Granit; Anne-Laure Grignon; Jonathan D Rohrer; Corey T McMillan; Murray Grossman; Ammar Al-Chalabi; Martin R Turner
Journal:  Brain       Date:  2022-03-29       Impact factor: 15.255

7.  Montreal Cognitive Assessment (MoCA) performance in Huntington's disease patients correlates with cortical and caudate atrophy.

Authors:  Gabriel Ramirez-Garcia; Victor Galvez; Rosalinda Diaz; Aurelio Campos-Romo; Juan Fernandez-Ruiz
Journal:  PeerJ       Date:  2022-04-04       Impact factor: 2.984

Review 8.  Novel Imaging Biomarkers for Huntington's Disease and Other Hereditary Choreas.

Authors:  Patrik Fazio; Martin Paucar; Per Svenningsson; Andrea Varrone
Journal:  Curr Neurol Neurosci Rep       Date:  2018-10-05       Impact factor: 5.081
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.